Over the last decades, a deeper understanding of multiple myeloma’s complex pathobiology has transformed the diagnosis, prognosis, and treatment paradigm, resulting in significant improvements in patient outcomes. Despite advances in treatment and outcomes, multiple myeloma is still considered an incurable disease. The management of newly diagnosed transplant-eligible patients and treatment approaches for relapsed/refractory myeloma remain hotly debated topics among the experts. The development of targeted and immune agents represents an important therapeutic strategy that can potentially translate into myeloma’s eventual cure.

In this exclusive podcast, María-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, Thomas Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, and Nina Shah, MD, University of California-San Francisco, San Francisco, CA, discuss the critical data presented at the ASH 2020 virtual Annual Meeting and how they might influence the treatment paradigm in myeloma.

The post The Myeloma Sessions: key updates from ASH 2020 appeared first on VJHemOnc.